Compare AESI & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AESI | ELVN |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2023 | 2020 |
| Metric | AESI | ELVN |
|---|---|---|
| Price | $8.90 | $16.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | $16.32 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 2.3M | 798.5K |
| Earning Date | 11-03-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,117,218,000.00 | N/A |
| Revenue This Year | $4.64 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.68 | N/A |
| 52 Week Low | $7.64 | $13.30 |
| 52 Week High | $26.86 | $25.37 |
| Indicator | AESI | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 37.75 |
| Support Level | $9.19 | $15.71 |
| Resistance Level | $9.81 | $18.05 |
| Average True Range (ATR) | 0.48 | 1.39 |
| MACD | 0.00 | -0.19 |
| Stochastic Oscillator | 11.96 | 10.61 |
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.